This is good. Until this point, there have been few (if any) mentions of leronlimab and mTNBC in scientific literature. This is important as we need more oncologists to be aware of leronlimab for trial enrollment and support.

And as far as I can tell, Targeted Oncology is a legit a scientific peer-reviewed journal with a decent online presence:

About Us
Targeted Healthcare Communications leverages the growing interest in cancer products in precision medicine and is the first publisher with a peer-reviewed journal focusing on these new products. Through our digital and print media platforms, we offer a dedicated website and publication as well as a number of multichannel programs focused on precision medicine in oncology.

Targeted Therapies in Oncology is dedicated to providing oncology healthcare professionals with leading-edge research, data, and treatment strategies surrounding molecular and immune system targets that may significantly improve outcomes for patients with cancer. The publication translates the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.

TargetedOnc.com™ has a unique focus on molecular biology with expert opinions on research, management, and treatment. This oncology-focused website provides content focused on precision medicine in oncology. As cancer research continues to trend toward systems biology and molecular aberrations, the challenge facing many oncologists is staying current and up-to-date with the future of cancer therapeutics.